With trastuzumab biosimilars expected on the US market soon for HER2-positive breast cancer, an advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of the medicines to lower costs and provide more treatment options.
With trastuzumab biosimilars expected on the US market soon for HER2-positive breast cancer, an advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of the medicines to lower costs and provide more treatment options.
Trastuzumab attaches to the HER2 protein on the surface of the cancer cell, slowing or stopping the cancer cell from growing. In the US market, patents on Roche’s Herceptin, the originator trastuzumab, are expiring this year, clearing the way for competitors.
Biosimilars of trastuzumab have already entered the European market, and in the United States, 5 biosimilars (Ogivri, Kanjinti, Herzuma, Ontruzant, and Trazimera) have been FDA approved, though none are yet available to patients.
“The introduction of biosimilars is an important step in increasing options for treating HER2-positive breast cancers, which account for about 25% of all breast cancers. As patient advocates, we are working to ensure that patients are educated about biosimilars and can feel comforted that they are FDA approved and just as safe and effective as the original biologic drug,” said Paula Schneider, chief executive officer of Susan G. Komen, in a statement.
Susan G. Komen said there are 4 things it wants patients to know about biosimilars:
Breast cancer groups are also preparing for the introduction of trastuzumab biosimilars in Canada, where biosimilars have been available since 2009. Health Canada approved its first trastuzumab biosimilar, Mylan and Biocon’s Ogivri, in May.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.